on INNATE PHARMA (EPA:IPH)
Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers
Innate Pharma SA announced new efficacy and safety results for SAR443579/IPH6101, an NK Cell Engager in development with Sanofi. At the European Hematology Association, data showed complete remissions in patients with relapsed or refractory acute myeloid leukemia.
SAR443579/IPH6101, targeting CD123 and engaging NKp46/CD16 receptors, demonstrated durable clinical responses. Complete remissions were observed at a dose of 1 mg/kg, some lasting more than 10 months. Sanofi is leading this Phase 1/2 trial, which will advance to Phase 2 with defined recommended doses.
Fifty-nine patients were treated, showing a maximal response rate with well-tolerated weekly doses of 6 mg/kg. The collaboration between Innate Pharma and Sanofi continues to progress, aiming to prove the potential of this innovative treatment for hematological cancers.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news